Compass Therapeutics, Inc. (CMPX) stock
Close on Nov 13, 2026Market cap $139.35MP/E –Yield –
Compass Therapeutics, Inc. saw revenue fall 100.0% to $0 over fiscal 2025. Free cash flow was -$61.94M. At the latest close the market valued the company at $139.35M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $139.35M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.98
- Dividend yield
- –
- Free cash flow yield
- -44.45%
Fundamentals
- Revenue
- $0
- Net income
- -$86.36M
- EPS, diluted
- -$0.46
- Free cash flow
- -$61.94M
- Book value per share
- $0.76
- Diluted shares
- 187M
Trading
- Next earnings
- Mar 4, 2027 (estimated, before the open)
- Previous close
- $0.82
- Open
- $0.83
- Day's range
- $0.75 – $0.83
- Volume
- 1,550,026
- Average volume (20 days)
- 2,068,198
- Index membership
- Russell 2000 (since Jun 2023), Russell 3000 (since Aug 2023)
- Beta (5 years)
- 1.26
- 52-week range
- $0.67 – $6.88
- RSI (14 days)
- 37.2
- Volatility (1 year)
- 96.2%
- Relative volume
- 0.42×
- WACC
- 11.4%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | CMPX | S&P 500 | Difference | CMPX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -9.7% | -3.0% | −6.7 pts | ||
| 3 months | -65.8% | -2.8% | −63.0 pts | ||
| Year to date | -85.6% | +11.5% | −97.1 pts | ||
| 1 year | -83.8% | +13.5% | −97.2 pts | ||
| 3 years | -44.7% | +77.7% | −122.4 pts | -17.9% | +21.1% |
| 5 years | -78.2% | +72.6% | −150.8 pts | -26.3% | +11.5% |
Eight years at a glance
Fiscal years 2018 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Compass Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Update
- Results
- Update
About Compass Therapeutics
Biological Products, (No Diagnostic Substances)
Compass Therapeutics is a clinical-stage biopharmaceutical company that develops proprietary antibody-based therapeutics for treating human diseases, primarily solid tumors and hematologic cancers. The company focuses on the biological relationship between angiogenesis, tumor growth, and the immune system. Its pipeline consists of four clinical-stage candidates: tovecimig, an antibody targeting DLL4 and VEGF-A; CTX-471, an agonist antibody targeting CD137; CTX-8371, an antibody targeting PD-1 and PD-L1; and CTX-10726, targeting PD-1 and VEGF-A. The company aims its therapeutic candidates at patients suffering from diverse malignancies, including biliary tract, colorectal, non-small cell lung, and triple-negative breast cancers.
Company profile, executives and historyCompass Therapeutics stock: common questions
What is Compass Therapeutics's stock price?
CMPX closed at $0.77 on Nov 13, 2026, down 5.63% on the day. Over the past 52 weeks it traded between $0.67 and $6.88.
What is Compass Therapeutics's market cap?
Compass Therapeutics was worth $139.35M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is CMPX's P/E ratio?
Compass Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.46), so it has no meaningful P/E ratio.
How much revenue does Compass Therapeutics make?
Compass Therapeutics reported revenue of $0 for fiscal 2025, down 100.0% from a year earlier.
Does Compass Therapeutics pay a dividend?
No. Compass Therapeutics has not paid a cash dividend over the last twelve months.
When does Compass Therapeutics report earnings next?
Compass Therapeutics is expected to report Q4 FY2026 results on Mar 4, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has CMPX stock performed over the past year?
Including dividends, CMPX returned -83.8% over the past year, against +13.5% for the S&P 500.
How many CMPX shares are sold short?
41M shares were sold short at the latest FINRA report, 30.75% of the float, or 18.9 days of average trading volume.
Who are Compass Therapeutics's competitors?
Companies most similar to Compass Therapeutics by business, industry and size include INBX, IMA, CRDF, PALI, ABPO.
See a number that looks wrong?